13,14-二氢-15-氧代前列腺素 F2alpha | 27376-76-7

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 13,14-二氢-15-氧代前列腺素 F2alpha
• 中文别名: 13,14-二氢-15-氧代前列腺素F2alpha
• 英文名称: 13,14-dihydro-15-keto-prostaglandin F_2α
• 英文别名: DKF2alpha；13,14-Dihydro-15-keto-pgf2alpha；(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
• CAS: 27376-76-7
• 化学式: C₂₀H₃₄O₅
• 分子量: 354.487
• InChiKey: VKTIONYPMSCHQI-XAGFEHLVSA-N

物化性质

• 沸点：
  543.0±40.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：>100 mg/ml（来自 PGF2a）； DMSO：>100 mg/ml（来自 PGF2a）；乙醇：>100 mg/ml（来自 PGF2a）； PBS pH 7.2：>10 mg/ml（来自 PGF2a）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 安全说明：
  S22,S36

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 13,14-Dihydro-15-ketoprostaglandin F2α
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 27376-76-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Inhalation (Category 4), H332
Acute toxicity, Dermal (Category 4), H312
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R20/21/22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H312 Harmful in contact with skin.
H332 Harmful if inhaled.
Precautionary statement(s)
P280 Wear protective gloves/ protective clothing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C20H34O5
Molecular Weight : 354,48 g/mol
CAS-No. : 27376-76-7
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
13,14-Dihydro-15-ketoprostaglandin F2α
Acute Tox. 4; H302, H312, -
H332
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
13,14-Dihydro-15-ketoprostaglandin F2α
Xn, R20/21/22 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Normal measures for preventive fire protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: -20 °C
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
H312 Harmful in contact with skin.
H332 Harmful if inhaled.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R20/21/22 Harmful by inhalation, in contact with skin and if swallowed.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  13,14-二氢-15-氧代前列腺素 F2alpha 在 potassium phosphate 、 β-烟酰胺腺嘌呤二核苷酸 、 MSFKQQCVELSDGRLMPLLGYGRFQNPEIPASKILESTKIAIDIGFRHIDSAYVYKNEKEVGEAIRSKITGGVVKREDIFLTTKLWSTFHRPELMRVGLERSLKSFOLDYVDLYLHYPISIKPGEEIYTKDENGKILFETVDLCAIWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKHRPVCNQVECHPYLNQSKLMDFCKSQDIVLVAYAALGSQRPTNWVDKNAPFLLNDPVLGGMAKKHNRSPAQIALRYQVQRGVVALAQTYEQKEMKENIQVFEFQLPSEDMEVILGLNRNFLRFPVNIAAEHPNYPYSDDY 、 MSSKQQLVKLNDGHFIPALGFGTYKPEEVPENKPLEAIHLAVEAGFRHIDTAYVYQTENHVGQAIKSKIAAGIVKREDIFITTKLWCTFHRPEMVLSSLEKSKNKQKDYVDLYIIHYPMQMKSGEDMFPEDENGKTLFDTVDLCATWEAMEKCKDAGLAKSIGISNFNRRQLEKILNKPGLKYKPVCNQVECHLYLNQSKLLNYKSRDIVLVAYCALGSQRPKRWVDPSSPVLLNDPVLCDVAKKHQRSSAQIALRYQLQRGIVVLAQSYKENEIKENIQVFEFELPSEDMKILDSLDRNLRYAPAPFGQGHPEYPFSDEF 作用下， 生成 13,14-二氢-15-氧代前列腺素E1
  参考文献：
  名称：

  Characterization of aldo-keto reductase 1C subfamily members encoded in two rat genes (akr1c19 and RGD1564865). Relationship to 9-hydroxyprostaglandin dehydrogenase

  摘要：

  DOI：

  10.1016/j.abb.2021.108755
• 作为产物：
  描述：

  1-[(3aR,4R,5R,6aS)-2,5-dihydroxy-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]furan-4-yl]octan-3-one 、 (4-carboxybutyl)triphenylphosphonium bromide 生成 13,14-二氢-15-氧代前列腺素 F2alpha
  参考文献：
  名称：

  MARCZAK, S.;WICHA, J., SYNTH. COMMUN., 19,(1989) N-4, C. 633-639

  摘要：

  DOI：

文献信息

• [EN] KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR<br/>[FR] INTERMÉDIAIRE CLÉ POUR LA SYNTHÈSE DE COMPOSÉS DE PROSTAGLANDINE ET SON PROCÉDÉ DE PRÉPARATION<br/>[ZH] 一类前列腺素类化合物合成关键中间体及其制备方法
  申请人：SHENZHEN CATALYS TECH CO LTD

  公开号：WO2022057734A1

  公开（公告）日：2022-03-24

  本发明涉及有机化工技术领域，特别是一类前列腺素类化合物合成关键中间体及其制备方法。应用于前列腺素类化合物合成时，简化了工艺流程，并且提高了收率和产物纯度，降低了生产成本，易于产业化应用。
• Prostaglandins of the D series, and tranquilizers and soporifics
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

  公开号：US05534547A1

  公开（公告）日：1996-07-09

  The present invention provides novel prostaglandins D, that is, 13,14-dihydro-15-keto-PGDs, whieh have an excellent sedative and sleep-inducing activity, and so they are useful for tranquilizer and/or soporifics.

  本发明提供了一种新型前列腺素D，即13,14-二氢-15-酮-PGDs，具有优异的镇静和催眠作用，因此它们可用于镇定剂和/或催眠剂。
• MARCZAK, S.;WICHA, J., SYNTH. COMMUN., 19,(1989) N-4, C. 633-639
  作者：MARCZAK, S.、WICHA, J.

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS RELATING TO LIPOKINES FOR TREATING METABOLIC DISORDERS
  申请人：Joslin Diabetes Center, Inc.

  公开号：US20210161848A1

  公开（公告）日：2021-06-03

  The invention includes methods and compositions for treating a metabolic disorder, such as metabolic syndrome, hyperlipidemia and associated disorders, such as obesity and diabetes. The invention includes a method of treating a human subject comprising administering 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) to the subject. The invention also includes methods and compositions for treating disorders and conditions that would benefit from skeletal muscle fatty acid uptake and oxidation, increased mitochondrial respiration in skeletal muscle and/or enhanced exercise capacity.
• Characterization of aldo-keto reductase 1C subfamily members encoded in two rat genes (akr1c19 and RGD1564865). Relationship to 9-hydroxyprostaglandin dehydrogenase
  作者：Satoshi Endo、Toshiyuki Matsunaga、Akira Hara

  DOI：10.1016/j.abb.2021.108755

  日期：2021.3